These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8611376)

  • 41. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
    J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [LH-RH analogue for the treatment in premenopausal, receptor-positive breast cancer].
    Sano M; Makino H
    Nihon Rinsho; 2000 Apr; 58 Suppl():328-33. PubMed ID: 11026014
    [No Abstract]   [Full Text] [Related]  

  • 43. Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea.
    Kim HJ; Lee JS; Park EH; Lim WS; Sei JY; Koh BS; Son BH; Ahn JH; Jeong KH; Kim SB; Ahn SH
    Eur J Surg Oncol; 2009 Sep; 35(9):936-41. PubMed ID: 19269125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
    Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
    J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient.
    Jonat W; Pritchard KI; Sainsbury R; Klijn JG
    J Cancer Res Clin Oncol; 2006 May; 132(5):275-86. PubMed ID: 16435142
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
    Barbie TU; Ma C; Margenthaler JA
    Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
    Thewes B; Meiser B; Duric VM; Stockler MR; Taylor A; Stuart-Harris R; Links M; Wilcken N; McLachlan SA; Phillips KA; Beith J; Boyle F; Friedlander ML
    Lancet Oncol; 2005 Aug; 6(8):581-8. PubMed ID: 16054569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
    Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
    Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant endocrine therapy for premenopausal hormone receptor-positive breast cancer; much done, more to do.
    Higgins MJ; Wolf AC
    Oncology (Williston Park); 2009 Jan; 23(1):40, 42, 44. PubMed ID: 19283920
    [No Abstract]   [Full Text] [Related]  

  • 50. Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience.
    Mathew J; Asgeirsson KS; Agrawal A; Mukherjee A; Ellis IO; Cheung KL; Chan SY; Robertson JF
    Eur J Surg Oncol; 2007 Oct; 33(8):972-6. PubMed ID: 17391905
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomised trial of chemotherapy versus endocrine therapy in patients presenting with locally advanced breast cancer (a pilot study).
    Gazet JC; Ford HT; Coombes RC
    Br J Cancer; 1991 Feb; 63(2):279-82. PubMed ID: 1825469
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
    Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
    Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients.
    Shimizu D; Ishikawa T; Tanabe M; Sasaki T; Ichikawa Y; Chishima T; Endo I
    Breast Cancer; 2014 Sep; 21(5):557-62. PubMed ID: 23184499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study.
    Takuwa H; Saji S; Takada M; Takahara S; Yamauchi A
    Breast Dis; 2018; 37(4):185-190. PubMed ID: 29578459
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Prognostic and therapeutic significance of steroid receptors in invasive breast cancer].
    Wyss P; Rageth JC; Unger C; Hochuli E
    Geburtshilfe Frauenheilkd; 1992 Oct; 52(10):611-6. PubMed ID: 1294437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant endocrine therapy.
    Rutqvist LE
    Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):81-95. PubMed ID: 14687599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer--another step forward.
    Pater JL; Parulekar WR
    J Natl Cancer Inst; 2003 Dec; 95(24):1811-2. PubMed ID: 14679143
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.